Immunotherapy in Prepatients-Preventing or Promoting a Malignant Transformation?

Bishal Gyawali^{1

2

3}, Garth W Strohbehn^{4

5}

Affiliations

¹ Department of Oncology, Queen's University, Kingston, Canada.
² Department of Public Health Sciences, Queen's University, Kingston, Canada.
³ Division of Cancer Care and Epidemiology, Queen's University, Kingston, Canada.
⁴ Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.
⁵ Rogel Cancer Center, University of Michigan, Ann Arbor.

Comment

Bishal Gyawali et al. JAMA Oncol. 2024.

. 2024 Jan 1;10(1):41-42.

doi: 10.1001/jamaoncol.2023.4799.

Bishal Gyawali^{1

2

3}, Garth W Strohbehn^{4

5}

¹ Department of Oncology, Queen's University, Kingston, Canada.
² Department of Public Health Sciences, Queen's University, Kingston, Canada.
³ Division of Cancer Care and Epidemiology, Queen's University, Kingston, Canada.
⁴ Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.
⁵ Rogel Cancer Center, University of Michigan, Ann Arbor.

No abstract available

Comment on

Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
Hanna GJ, Villa A, Nandi SP, Shi R, ONeill A, Liu M, Quinn CT, Treister NS, Sroussi HY, Vacharotayangul P, Goguen LA, Annino DJ Jr, Rettig EM, Jo VY, Wong KS, Lizotte P, Paweletz CP, Uppaluri R, Haddad RI, Cohen EEW, Alexandrov LB, William WN Jr, Lippman SM, Woo SB. Hanna GJ, et al. JAMA Oncol. 2024 Jan 1;10(1):32-41. doi: 10.1001/jamaoncol.2023.4853. JAMA Oncol. 2024. PMID: 37971722 Free PMC article.